NIP
KRYS icon

Nicholas Investment Partners’s Krystal Biotech KRYS Stock Holding History

Nicholas Investment Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,086
Closed -$797K – 217
2024
Q4 		$797K Sell
5,086
-13,721
-73% -$2.43M 0.07% 196
2024
Q3 		$3.42M Buy
18,807
+1,480
+9% +$285K 0.31% 124
2024
Q2 		$3.18M Buy
+17,327
New +$2.91M 0.33% 113
2024
Q1 		– Sell
-49,073
Closed -$6.09M – 215
2023
Q4 		$6.09M Sell
49,073
-306,538
-86% -$34M 0.71% 46
2023
Q3 		$41.3M Sell
355,611
-19,340
-5% -$2.36M 3.08% 2
2023
Q2 		$44M Buy
374,951
+233
+0.1% +$23.8K 3.01% 1
2023
Q1 		$30M Buy
374,718
+107,629
+40% +$8.46M 2.28% 4
2022
Q4 		$21.2M Buy
267,089
+45,063
+20% +$3.34M 1.85% 8
2022
Q3 		$15.5M Sell
222,026
-5,851
-3% -$423K 1.43% 17
2022
Q2 		$15M Sell
227,877
-855
-0.4% -$53.2K 1.41% 19
2022
Q1 		$15.2M Buy
228,732
+37,421
+20% +$2.34M 1.08% 28
2021
Q4 		$13.4M Sell
191,311
-65,564
-26% -$3.82M 0.85% 39
2021
Q3 		$13.4M Sell
256,875
-56,579
-18% -$3.35M 0.98% 30
2021
Q2 		$21.3M Buy
313,454
+8,765
+3% +$612K 1.34% 17
2021
Q1 		$23.5M Buy
304,689
+71,146
+30% +$5.17M 1.64% 8
2020
Q4 		$14M Buy
233,543
+11,121
+5% +$555K 1.08% 29
2020
Q3 		$9.57M Buy
222,422
+182,914
+463% +$7.94M 1.04% 34
2020
Q2 		$1.64M Sell
39,508
-42,408
-52% -$2.04M 0.33% 113
2020
Q1 		$3.54M Buy
81,916
+7,498
+10% +$392K 0.69% 54
2019
Q4 		$4.12M Sell
74,418
-35,409
-32% -$1.74M 0.42% 79
2019
Q3 		$3.81M Sell
109,827
-402
-0.4% -$18K 0.32% 124
2019
Q2 		$4.44M Sell
110,229
-996
-0.9% -$32.6K 0.41% 88
2019
Q1 		$3.66M Sell
111,225
-19,751
-15% -$466K 0.33% 105
2018
Q4 		$2.72M Buy
+130,976
New +$2.74M 0.29% 129

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nicholas Investment Partners's KRYS Position: Q1 2025 in Review

Nicholas Investment Partners sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 5,086 shares — an estimated $797K sold.

Nicholas Investment Partners first reported a position in KRYS in Q4 2018 and held it in 24 quarters. The position peaked at $44M in Q2 2023. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Nicholas Investment Partners reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Nicholas Investment Partners sold 5,086 Krystal Biotech shares in Q1 2025, an estimated $797K.
  • Nicholas Investment Partners first reported a position in Krystal Biotech in Q4 2018 and held it in 24 quarters.
  • Nicholas Investment Partners's Krystal Biotech position peaked at $44M in Q2 2023.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Nicholas Investment Partners's 13F filing for Q1 2025, filed 15 May 2025.